From human genetics to drug candidates: An industrial perspective on lrrk2 inhibition as a treatment for parkinson's disease

Medicinal Chemistry Approaches to Personalized Medicine

Volumn 59, Issue , 2013, Pages 227-254

  Zhu, Haitao ^a   Chen, Huifen ^a   Cho, William ^a   Estrada, Anthony A ^a   Sweeney, Zachary K ^b  

^a GENENTECH INC   (United States)

^b NOVARTIS   (United States)

Author keywords

Drug discovery; Familial PD; Kinase activity; Leucine rich repeat kinase 2; Neurodegenerative disease; Parkinson's disease

Indexed keywords

EID: 85017403624     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527677252.ch10     Document Type: Chapter

References (104)

1. de Rijk, M.C., Launer, L.J., Berger, K., Breteler, M.M., Dartigues, J.F., Baldereschi, M., Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C., and Hofman, A. (2000) Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology, 54 (11 Suppl. 5), S21-S23.
2. Meissner, W.G., Frasier, M., Gasser, T., Goetz, C.G., Lozano, A., Piccini, P., Obeso, J.A., Rascol, O., Schapira, A., Voon, V., Weiner, D.M., Tison, F., and Bezard, E. (2011) Priorities in Parkinson's disease research. Nature Reviews. Drug Discovery,10. (5), 377-393.
3. Schapira, A.H. (2006) Etiology of Parkinson's disease. Neurology, 66 10 (Suppl. 4), S10-S13.
4. Dachsel, J.C. and Farrer, M.J. (2010) LRRK2 and Parkinson disease. Archives of Neurology, 67 (5), 542-547.
5. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A. M., Khan, N., Johnson, J., Martinez, J.R., Nicholl, D., Carrera, I.M., Pena, A.S., de Silva, R., Lees, A., Marti-Masso, J.F., Perez-Tur, J., Wood, N.W., and Singleton, A.B. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44 (4), 595-600.
6. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, I.C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, T.M.,Wszolek, Z.K., and Gasser, T. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44 (4), 601-607.
7. Aasly, J.O., Vilarino-Guell, C., Dachsel, J. C., Webber, P.J., West, A.B., Haugarvoll, K., Johansen, K.K., Toft, M., Nutt, J.G., Payami, H., Kachergus, J.M., Lincoln, S.J., Felic, A., Wider, C., Soto-Ortolaza, A.I., Cobb, S.A., White, L.R., Ross, O.A., and Farrer, M.J. (2010) Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Movement Disorders, 25 (13), 2156-2163.
8. Ross, O.A., Spanaki, C., Griffith, A., Lin, C.H., Kachergus, J., Haugarvoll, K., Latsoudis, H., Plaitakis, A., Ferreira, J.J., Sampaio, C., Bonifati, V., Wu, R.M., Zabetian, C.P., and Farrer, M.J. (2009) Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism & Related Disorders, 15 (6), 466-467.
9. Hernandez, D., Paisan Ruiz, C., Crawley, A., Malkani, R., Werner, J., Gwinn-Hardy, K., Dickson, D., Wavrant Devrieze, F., Hardy, J., and Singleton, A. (2005) The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neuroscience Letters, 389 (3), 137-139.
10. Di Fonzo, A., Wu-Chou, Y.H., Lu, C.S., van Doeselaar, M., Simons, E.J., Rohe, C.F., Chang, H.C., Chen, R.S., Weng, Y.H., Vanacore, N., Breedveld, G.J., Oostra, B.A., and Bonifati, V. (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics, 7 (3), 133-138.
11. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., Tomiyama, H., Nakashima, K., Hasegawa, K., Obata, F., Yoshikawa, T., Kawakami, H., Sakoda, S., Yamamoto, M., Hattori, N., Murata, M., Nakamura, Y., and Toda, T. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics, 41 (12), 1303-1307.
12. Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G., Kruger, R., Federoff, M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M.A., Illig, T., Gieger, C., Houlden, H., Steffens, M., Okun, M.S., Racette, B.A., Cookson, M.R., Foote, K.D., Fernandez, H.H., Traynor, B.J., Schreiber, S., Arepalli, S., Zonozi, R., Gwinn, K., van der Brug, M., Lopez, G., Chanock, S.J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X., Wood, N.W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J.A., Singleton, A.B., and Gasser, T. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 41 (12), 1308-1312.
13. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L., and Dawson, T.M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 102 (46), 16842-16847.
14. Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A., and Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. The Biochemical Journal, 405 (2), 307-317.
15. Nichols, R.J., Dzamko, N., Hutti, J.E., Cantley, L.C., Deak, M., Moran, J., Bamborough, P., Reith, A.D., and Alessi, D.R. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. The Biochemical Journal, 424 (1), 47-60.
16. Lovitt, B., Vanderporten, E.C., Sheng, Z., Zhu, H., Drummond, J., and Liu, Y. (2010) Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). Biochemistry, 49 (14), 3092-3100.
17. Covy, J.P. and Giasson, B.I. (2009) Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochemical and Biophysical Research Communications, 378 (3), 473-477.
18. Greggio, E. and Cookson, M.R. (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuroscience, 1 (1), 13-24.
19. Pungaliya, P.P., Bai, Y., Lipinski, K., Anand, V.S., Sen, S., Brown, E.L., Bates, B., Reinhart, P.H., West, A.B., Hirst, W.D., and Braithwaite, S.P. (2010) Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One, 5 (10), e13672.
20. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L., and Dawson, T.M. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics, 16 (2), 223-232.
21. Webber, P.J., Smith, A.D., Sen, S., Renfrow, M.B., Mobley, J.A., and West, A. B. (2011) Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTPbinding activities. Journal of Molecular Biology, 412 (1), 94-110.
22. Greggio, E., Taymans, J.M., Zhen, E.Y., Ryder, J., Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H., Baekelandt, V., Merchant, K., and Cookson, M.R. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochemical and Biophysical Research Communications, 389 (3), 449-454.
23. Kamikawaji, S., Ito, G., and Iwatsubo, T. (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry, 48 (46), 10963-10975.
24. Gloeckner, C.J., Boldt, K., von Zweydorf, F., Helm, S., Wiesent, L., Sarioglu, H., and Ueffing, M. (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. Journal of Proteome Research, 9 (4), 1738-1745.
25. Guo, L., Gandhi, P.N., Wang, W., Petersen, R.B., Wilson-Delfosse, A.L., and Chen, S.G. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Experimental Cell Research, 313 (16), 3658-3670.
26. Li, X., Tan, Y.C., Poulose, S., Olanow, C.W., Huang, X.Y., and Yue, Z. (2007) Leucinerich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. Journal of Neurochemistry, 103 (1), 238-247.
27. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T., and Iwatsubo, T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry, 46 (5), 1380-1388.
28. Deng, J., Lewis, P.A., Greggio, E., Sluch, E., Beilina, A., and Cookson, M.R. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proceedings of the National Academy of Sciences of the United States of America, 105 (5), 1499-1504.357. (3), 668-671.
29. Taymans, J.M., Vancraenenbroeck, R., Ollikainen, P., Beilina, A., Lobbestael, E., De Maeyer, M., Baekelandt, V., and Cookson, M.R. (2011) LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One, 6 (8), e23207.
30. Liu, M., Dobson, B., Glicksman, M.A., Yue, Z., and Stein, R.L. (2010) Kinetic mechanistic studies of wild-type leucinerich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry,49. (9), 2008-2017.
31. Smith,W.W., Pei, Z., Jiang, H., Moore, D. J., Liang, Y., West, A.B., Dawson, V.L., Dawson, T.M., and Ross, C.A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 102 (51), 18676-18681.
32. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J., Ahmad, R., Miller, D.W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R.J., Harvey, K., and Cookson, M.R. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiology of Disease,23. (2), 329-341.
33. Smith,W.W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T.M., and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience, 9 (10), 1231-1233.
34. Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carri, M.T., and Barone, P. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Human Molecular Genetics, 16 (11), 1319-1326.
35. Ho, C.C., Rideout, H.J., Ribe, E., Troy, C. M., and Dauer, W.T. (2009) The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. The Journal of Neuroscience, 29 (4), 1011-1016.
36. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 52 (4), 587-593.
37. Plowey, E.D., Cherra, S.J., III, Liu, Y.J., and Chu, C.T. (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. Journal of Neurochemistry, 105 (3), 1048-1056.
38. Wang, L., Xie, C., Greggio, E., Parisiadou, L., Shim, H., Sun, L., Chandran, J., Lin, X., Lai, C., Yang, W.J., Moore, D.J., Dawson, T. M., Dawson, V.L., Chiosis, G., Cookson, M.R., and Cai, H. (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. The Journal of Neuroscience,28. (13), 3384-3391.
39. Stafa, K., Trancikova, A., Webber, P.J., Glauser, L., West, A.B., and Moore, D.J. (2012) GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genetics, 8 (2), e1002526.
40. Lee, B.D., Shin, J.H., VanKampen, J., Petrucelli, L.,West, A.B., Ko, H.S., Lee, Y.I., Maguire-Zeiss, K.A., Bowers,W.J., Federoff, H.J., Dawson, V.L., and Dawson, T.M. (2010) Inhibitors of leucinerich repeat kinase-2 (LRRK 2) protect against LRRK 2-models of Parkinson's disease. Nature Medicine, 16 (9), 998-1000.
41. Ramsden, N., Perrin, J., Ren, Z., Lee, B.D., Zinn, N., Dawson, V.L., Tam, D., Bova, M., Lang, M., Drewes, G., Bantscheff, M., Bard, F., Dawson, T.M., and Hopf, C. (2011) Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chemical Biology, 6 (10), 1021-1028.
42. Deachsel, J.C., Behrouz, B., Yue, M., Beevers, J.E., Melrose, H.L., and Farrer, M. J. (2010) A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism & Related Disorders, 16 (10), 650-655.
43. Imai, Y., Gehrke, S., Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E., and Lu, B. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO Journal, 27 (18), 2432-2443.
44. Drolet, R.E., Sanders, J.M., and Kern, J.T. (2011) Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions. Journal of Neurogenetics, 25 (4), 140-151.
45. Dzamko, N., Deak, M., Hentati, F., Reith, A.D., Prescott, A.R., Alessi, D.R., and Nichols, R.J. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. The Biochemical Journal, 430 (3), 405-413.
46. Li, X.,Wang, Q.J., Pan, N., Lee, S., Zhao, Y., Chait, B.T., and Yue, Z. (2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One, 6 (3), e17153.
47. Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C.E., Dominguez, S.L., Solanoy, H.O., Drummond, J., Zhang, X., Ding, X., Cai, F., Song, Q., Li, X., Yue, Z., van der Brug, M.P., Burdick, D.J., Gunzner-Toste, J., Chen, H., Liu, X., Estrada, A.A., Sweeney, Z.K., Scearce-Levie, K., Moffat, J.G., Kirkpatrick, D.S., and Zhu, H. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Science Translational Medicine,4. (164), 164ra161.
48. Bov±e, J., Prou, D., Perier, C., and Przedborski, S. (2005) Toxin-induced models of Parkinson's disease. NeuroRx, 2 (3), 484-494.512. (7), 826-828.
49. Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., Danner, S., Schnell, C.R., Mueller, M., Kinzel, B., Grevot, A., Bolognani, F., Stirn, M., Kuhn, R.R., Kaupmann, K., van der Putten, P.H., Rovelli, G., and Shimshek, D.R. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Human Molecular Genetics, 20 (21), 4209-4223.
50. Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E.N., and Shen, J. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proceedings of the National Academy of Sciences of the United States of America, 106 (34), 14622-14627.
51. Ramonet, D., Daher, J.P., Lin, B.M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D.A., Beal, M.F., Troncoso, J.C., McCaffery, J.M., Jenkins, N.A., Copeland, N.G., Galter, D., Thomas, B., Lee, M.K., Dawson, T.M., Dawson, V.L., and Moore, D.J. (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One, 6 (4), e18568.
52. Dusonchet, J., Kochubey, O., Stafa, K., Young, S.M., Jr., Zufferey, R., Moore, D.J., Schneider, B.L., and Aebischer, P. (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. The Journal of Neuroscience, 31 (3), 907-912.
53. Andres-Mateos, E., Mejias, R., Sasaki, M., Li, X., Lin, B.M., Biskup, S., Zhang, L., Banerjee, R., Thomas, B., Yang, L., Liu, G., Beal, M.F., Huso, D.L., Dawson, T.M., and Dawson, V.L. (2009) Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). The Journal of Neuroscience, 29 (50), 15846-15850.
54. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R.J., III, and Shen, J. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences of the United States of America,107. (21), 9879-9884.
55. Hinkle, K.M., Yue, M., Behrouz, B., Dachsel, J.C., Lincoln, S.J., Bowles, E.E., Beevers, J.E., Dugger, B., Winner, B., Prots, I., Kent, C.B., Nishioka, K., Lin,W. L., Dickson, D.W., Janus, C.J., Farrer, M.J., and Melrose, H.L. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Molecular Neurodegeneration, 7, 25.
56. Khan, N.L., Jain, S., Lynch, J.M., Pavese, N., Abou-Sleiman, P., Holton, J.L., Healy, D.G., Gilks, W.P., Sweeney, M.G., Ganguly, M., Gibbons, V., Gandhi, S., Vaughan, J., Eunson, L.H., Katzenschlager, R., Gayton, J., Lennox, G., Revesz, T., Nicholl, D., Bhatia, K.P., Quinn, N., Brooks, D., Lees, A.J., Davis, M.B., Piccini, P., Singleton, A.B., and Wood, N.W. (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 128 (Part 12), 2786-2796.
57. Olanow, C.W., Stern, M.B., and Sethi, K. (2009) The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 72 (21 Suppl. 4), S1-S136.
58. Stoessl, A.J. (2011) Neuroimaging in Parkinson's disease. Neurotherapeutics, 8 (1), 72-81.
59. Pavese, N. and Brooks, D.J. (2009) Imaging neurodegeneration in Parkinson's disease. Biochimica et Biophysica Acta, 1792 (7), 722-729.
60. Hernandez, D.G., Paisan-Ruiz, C., McInerney-Leo, A., Jain, S., Meyer-Lindenberg, A., Evans, E.W., Berman, K.F., Johnson, J., Auburger, G., Schaffer, A.A., Lopez, G.J., Nussbaum, R.L., and Singleton, A.B. (2005) Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Annals of Neurology, 57 (3), 453-456.
61. Adams, J.R., van Netten, H., Schulzer, M., Mak, E., McKenzie, J., Strongosky, A., Sossi, V., Ruth, T.J., Lee, C.S., Farrer, M., Gasser, T., Uitti, R.J., Calne, D.B., Wszolek, Z.K., and Stoessl, A.J. (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain, 128 (Part 12), 2777-2785.
62. Sossi, V., de la Fuente-Fernandez, R., Nandhagopal, R., Schulzer, M., McKenzie, J., Ruth, T.J., Aasly, J.O., Farrer, M.J., Wszolek, Z.K., and Stoessl, J.A. (2010) Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Movement Disorders, 25 (16), 2717-2723.
63. Brockmann, K., Groger, A., Di Santo, A., Liepelt, I., Schulte, C., Klose, U., Maetzler, W., Hauser, A.K., Hilker, R., Gomez-Mancilla, B., Berg, D., and Gasser, T. (2011) Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Movement Disorders, 26 (13), 2335-2342.
64. Ahlskog, J.E. (2003) Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology, 60 (3), 381-389.
65. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C., and Marek, K. (2004) Levodopa and the progression of Parkinson's disease. The New England Journal of Medicine, 351 (24), 2498-2508.
66. Seibyl, J., Jennings, D., Tabamo, R., and Marek, K. (2004) Neuroimaging trials of Parkinson's disease progression. Journal of Neurology, 251 (Suppl 7), vii9-vii13.
67. Anonymous (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA: the journal of the American Medical Association, 287 (13), 1653-1661.
68. Winogrodzka, A., Bergmans, P., Booij, J., van Royen, E.A., Janssen, A.G., and Wolters, E.C. (2001) [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. Journal of Neural Transmission, 108 (8-9), 1011-1019.
69. Oehme, L., Perick, M., Beuthien-Baumann, B., Wolz, M., Storch, A., Lohle, M., Herting, B., Langner, J., van den Hoff, J., Reichmann, H., and Kotzerke, J. (2011) Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 38 (8), 1550-1559.
70. Anonymous (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. The New England Journal of Medicine, 328 (3), 176-183.
71. Healy, D.G., Falchi, M., O'Sullivan, S.S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C.P., Goldwurm, S., Ferreira, J.J., Tolosa, E., Kay, D.M., Klein, C., Williams, D.R., Marras, C., Lang, A.E., Wszolek, Z.K., Berciano, J., Schapira, A.H., Lynch, T., Bhatia, K.P., Gasser, T., Lees, A.J., and Wood, N.W. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, 7 (7), 583-590.
72. Hulihan, M.M., Ishihara-Paul, L., Kachergus, J., Warren, L., Amouri, R., Elango, R., Prinjha, R.K., Upmanyu, R., Kefi, M., Zouari, M., Sassi, S.B., Yahmed, S.B., El Euch-Fayeche, G., Matthews, P.M., Middleton, L.T., Gibson, R.A., Hentati, F., and Farrer, M. J. (2008) LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurology, 7 (7), 591-594.
73. Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science, 298 (5600), 1912-1934.
74. Liu, M., Kang, S., Ray, S., Jackson, J., Zaitsev, A.D., Gerber, S.A., Cuny, G.D., and Glicksman, M.A. (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucinerich repeat kinase 2 and the G2019S mutant. Biochemistry, 50 (43), 9399-9408.
75. Marin, I. (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. Molecular Biology and Evolution,23. (12), 2423-2433.
76. Yun, H., Heo, H.Y., Kim, H.H., DooKim, N., and Seol, W. (2011) Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein. Bioorganic & Medicinal Chemistry Letters,21. (10), 2953-2957.
77. Greggio, E., Zambrano, I., Kaganovich, A., Beilina, A., Taymans, J.M., Daniels, V., Lewis, P., Jain, S., Ding, J., Syed, A., Thomas, K.J., Baekelandt, V., and Cookson, M.R. (2008) The Parkinson disease-associated leucinerich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. The Journal of Biological Chemistry, 283 (24), 16906-16914.
78. Mata, I.F., Wedemeyer, W.J., Farrer, M.J., Taylor, J.P., and Gallo, K.A. (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends in Neuroscience, 29 (5), 286-293.
79. Zhang, J., Deng, X., Choi, H.G., Alessi, D.R., and Gray, N.S. (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorganic & Medicinal Chemistry Letters, 22 (5), 1864-1869.
80. Chen, H., Chan, B.K., Drummond, J., Estrada, A.A., Gunzner-Toste, J., Liu, X., Liu, Y., Moffat, J., Shore, D., Sweeney, Z. K., Tran, T., Wang, S., Zhao, G., Zhu, H., and Burdick, D.J. (2012) Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. Journal of Medicinal Chemistry,55. (11), 5536-5545.
81. Gilsbach, B.K., Ho, F.Y., Vetter, I.R., van Haastert, P.J., Wittinghofer, A., and Kortholt, A. (2012) Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proceedings of the National Academy of Sciences of the United States of America,109. (26), 10322-10327.
82. Kramer, T., Lo Monte, F., Goring, S., Okala Amombo, G.M., and Schmidt, B. (2012) Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chemical Neuroscience, 3 (3), 151-160.
83. Anand, V.S., Reichling, L.J., Lipinski, K., Stochaj, W., Duan, W., Kelleher, K., Pungaliya, P., Brown, E.L., Reinhart, P. H., Somberg, R., Hirst, W.D., Riddle, S. M., and Braithwaite, S.P. (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS Journal, 276 (2), 466-478.
84. Liu, Z., Hamamichi, S., Lee, B.D., Yang, D., Ray, A., Caldwell, G.A., Caldwell, K. A., Dawson, T.M., Smith, W.W., and Dawson, V.L. (2011) Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Human Molecular Genetics, 20 (20), 3933-3942.
85. Gerard, D., Hopf, C., and Reader, V. (2012) Methods for the identification of LRRK2 interacting molecules. US 8,163,511 B2 (Apr. 24, 2012).
86. Ramsden, N. (2009) The use of LRRK2 inhibitors for neurodegenerative diseases. WO 2009/127642 A2.
87. Goldstein, D.M., Gray, N.S., and Zarrinkar, P.P. (2008) High-throughput kinase profiling as a platform for drug discovery. Nature Reviews. Drug Discovery, 7 (5), 391-397.
88. Miduturu, C.V., Deng, X., Kwiatkowski, N., Yang, W., Brault, L., Filippakopoulos, P., Chung, E., Yang, Q., Schwaller, J., Knapp, S., King, R.W., Lee, J.D., Herrgard, S., Zarrinkar, P., and Gray, N.S. (2011) Highthroughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chemistry & Biology,18. (7), 868-879.
89. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.D., Patricelli, M.P., Nomanbhoy, T.K., Alessi, D.R., and Gray, N.S. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology, 7 (4), 203-205.
90. Deng, X., Yang, Q., Kwiatkowski, N., Sim, T., McDermott, U., Settleman, J.E., Lee, J.D., and Gray, N.S. (2011) Discovery of a benzo[e]pyrimido-[5,4-b] [1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACS Medicinal Chemistry Letters, 2 (3), 195-200.
91. Hitchcock, S.A. and Pennington, L.D. (2006) Structure-brain exposure relationships. Journal of Medicinal Chemistry, 49 (26), 7559-7583.
92. Reith, A.D., Bamborough, P., Jandu, K., Andreotti, D., Mensah, L., Dossang, P., Choi, H.G., Deng, X., Zhang, J., Alessi, D. R., and Gray, N.S. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-Narylbenzamide LRRK2 kinase inhibitor. Bioorganic & Medicinal Chemistry Letters, 22 (17), 5625-5629.
93. Doggett, E.A., Zhao, J., Mork, C.N., Hu, D., and Nichols, R.J. (2011) Phosphorylation of LRRK2 serines 955 and is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. Journal of Neurochemistry,120. (1), 37-45.
94. Andreotti, D., Dai, X., Eatherton, A.J., Jandu, K.S., Liu, Q., and Philps, O.J. (2012) 2-(Benzyloxy) benzamides as LRRK2 kinase inhibitors. WO 2012/028629. A1.
95. McCauley, J.A., Greshock, T.J., Sanders, J., Kern, J.T., Chang, R.K., and Stevenson, H. H. (2012) Compounds inhibiting leucinerich repeat kinase enzyme activity. WO 2012/118679.
96. McCauley, J.A., Rajapakse, H.A., Greshock, T.J., Sanders, J., Kim, B., Rada, V.L., Kern, J.T., Stevenson, H.H., and Bilodeau, M.T. (2012) Leucine-rich repeat kinase enzyme activity. WO 2012/058193 A1.
97. McIver, E.G., Smiljanic, E., Harding, D.J., and Hough, J. (2010) Compounds. WO 2010/106333 A1.
98. Chan, B., Chen, H., Estrada, A., Shore, D., Sweeney, Z., and McIver, E. (2012) Pyrazolopyridines as inhibitors of the kinase LRRK2. WO 2012/038743 A1.
99. Chan, B., Estrada, A., Sweeney, Z., and McIver, E. (2011) Pyrazolopyridines as inhibitors of the kinase LRRK2. WO 2011/141756. A1.
100. Baker-Glenn, C., Burdick, D.J., Chambers, M., Chen, H., Estrada, A., Sweeney, Z.K., and Chan, B.K. (2012) Pyrazole aminopyrimidine derivatives as LRRK2 modulators. WO 2012/062783 A1.
101. Baker-Glenn, C., Burdick, D.J., Chambers, M., Chan, B.K., Chen, H., Estrada, A., Gunzner, J.L., Shore, D., Sweeney, Z.K., Wang, S., and Zhao, G. (2011) Aminopyrimidine derivatives as LRRK2 modulators. WO 2011/151360 A1.
102. Estrada, A.A., Liu, X., Baker-Glenn, C., Beresford, A., Burdick, D.J., Chambers, M., Chan, B.K., Chen, H., Ding, X., DiPasquale, A.G., Dominguez, S.L., Dotson, J., Drummond, J., Flagella, M., Flynn, S., Fuji, R., Gill, A., Gunzner-Toste, J., Harris, S.F., Heffron, T.P., Kleinheinz, T., Lee, D.W., Le Pichon, C.E., Lyssikatos, J.P., Medhurst, A.D., Moffat, J.G., Mukund, S., Nash, K., Scearce-Levie, K., Sheng, Z., Shore, D.G., Tran, T., Trivedi, N., Wang, S., Zhang, S., Zhang, X., Zhao, G., Zhu, H., and Sweeney, Z.K. (2012) Discovery of highly potent, selective, and brainpenetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. Journal of Medicinal Chemistry, 55 (22), 9416-9433.
103. Choi, H.G., Zhang, J., Deng, X., Hatcher, J.M., Patricelli, M.P., Zhao, Z., Alessi, D.R., and Gray, N.S. (2012) Brain penetrant LRRK2 inhibitor. ACS Medicinal Chemistry Letters, 3 (8), 658-662.
104. Lewis, P.A. and Manzoni, C. (2012) LRRK2 and human disease: a complicated question or a question of complexes? Science Signaling, 5 (207), pe2.